Conflict of interest: Nothing to report.
Valvular and Structural Heart Diseases
Candidates for transcatheter aortic valve replacement
Fitting the PARTNERS criteria
Article first published online: 5 APR 2013
Copyright © 2012 Wiley Periodicals, Inc.
Catheterization and Cardiovascular Interventions
Volume 82, Issue 4, pages 655–661, 1 October 2013
How to Cite
Babcock, M. J., Lavine, S., Strom, J. A., Bass, T. A. and Guzman, L. A. (2013), Candidates for transcatheter aortic valve replacement. Cathet. Cardiovasc. Intervent., 82: 655–661. doi: 10.1002/ccd.24706
- Issue published online: 23 SEP 2013
- Article first published online: 5 APR 2013
- Accepted manuscript online: 16 OCT 2012 10:47AM EST
- Manuscript Accepted: 7 OCT 2012
- Manuscript Revised: 14 SEP 2012
- Manuscript Received: 31 AUG 2012
- aortic stenosis;
- transcatheter aortic valve replacement
To determine an estimate patient volume with severe AS meeting PARTNER-B criteria, with the objective of providing insights into the annual volume needed to sustain a TAVR program.
While the prevalence of AS is well documented, potential TAVR candidates remains less established. A better understanding of this population is critical for the development of TAVR programs. Though no clear volume has been determined, societies suggest a minimum of 20–24 annual cases to establish a TAVR program.
A total of 21,652 patients were screened from a single center echocardiography registry over a 3-year period. From them, 833 patients with AS were identified representing our study population. Severity was stratified by echocardiographic criteria. Those identified to have moderate-to-severe and severe AS were further investigated to determine clinical status and surgical candidacy. Nonsurgical candidates were cross referenced with the PARTNER-B exclusion criteria to determine eligibility for TAVR.
Symptomatic AS was present in 133 patients (16%). Fifty (38%) were considered nonsurgical candidates. Nonsurgical patients had higher STS score (11.1 ± 10.8 vs. 4.0 ± 3.3, P < 0.001). After applying PARTNERS-B exclusion criteria, only 18 patients (14%) were considered TAVR candidates. These findings indicate that to meet the recommended annual volume of 20–24 TAVR cases, a minimum of 150–170 symptomatic severe AS patients are required.
In real world clinical practice, the prevalence of AS meeting PARTNERS-B criteria for TAVR can be low. These findings suggest that either high volume valvular centers or regional referral centers will need to be considered as part of the strategy to incorporate this new technology into clinical practice. © 2012 Wiley Periodicals, Inc.